THE Pharmaceutical Benefits Advisory Committee has recommended the expansion of availability of Afluria Quad (inactivated quadrivalent influenza vaccine) to people aged 5-17 under the National Immunisation Program.
The full list of recommendations from the Nov 2018 PBAC meeting is online at pbs.gov.au.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Dec 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Dec 18
